GSK produced one vaccine in 1997 they currently produce 30 and are building more factories to produce them. The move in vaccine production has been to DNA based vaccines .
DNA vaccines are efficient at generating T-cell responses that may kill targeted cancerous cells or cells infected by the targeted virus or bacteria.
*
DNA vaccines may therefore also be used as a therapeutic to treat existing disease. This capability provides the potential to treat chronic infectious diseases such as HIV and hepatitis C virus, as well as the possibility to develop therapeutic cancer vaccines.
*
DNA vaccines can potentially be developed from concept to FDA approval in eight to 10 years, compared to the up to 20-year period it took to develop the chickenpox vaccine.
*
DNA vaccines can be readily manufactured using off-the-shelf, well-proven fermentation technology.
*
DNA vaccines ? in most cases ? do not require cold storage and distribution.
It may be to target this market that schott has built a new prefill factory
http://pmpnews.com/news/schott-begins-ready-fill-syringe-production-us
On examination of schotts promotional material re their prefills they do not mention either auto retract or auto disable for those interested the companys web site is at
http://www.us.schott.com/pharmaceutical_packaging/english/news/press.html?NID=2528
They may have a white elephant on their hands
vaccine market growth
Add UNI (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$5.00 |
Change
0.010(0.20%) |
Mkt cap ! $383.6M | |||
| Open | High | Low | Value | Volume |
| $5.01 | $5.03 | $4.90 | $431.8K | 86.63K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2000 | $4.97 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $5.05 | 5000 | 1 |
View Market Depth
| Last trade - 16.10pm 25/06/2024 (20 minute delay) ? |
| UNI (ASX) Chart |